NCT00801710

CrossBoss and Stingray Catheter and Entera Guidewire Chronic Total Occlusion (CTO) Study

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 42 (actual)
• Sponsor: Boston Scientific Corporation · Industry
• Sex: All
• Age: 19 Years
• Healthy volunteers: Not accepted

Summary

This study is to determine if the BridgePoint Medical System (CrossBoss Catheter, Stingray Catheter, Entera Guidewire) can facilitate safe and effective placement of a guidewire in the true lumen of coronary vessels distal to a chronic total occlusion (CTO). The hypothesis is that the BridgePoint Medical System can do this without an increase in major complications.

Conditions

• Coronary Artery Disease
• Coronary Artery Chronic Total Occlusion

Interventions

Type	Name	Description
DEVICE	BridgePoint Medical System (CrossBoss Catheter, Stingray Catheter, Entera Guidewire)	Revascularization of coronary artery chronic total occlusion. Use of the BridgePoint Medical System to cross coronary CTOs prior to definitive revascularization treatment via angioplasty and/or stent implant

Timeline

• Start date: 2008-09-01
• Primary completion: 2009-06-01
• Completion: 2009-09-01
• First posted: 2008-12-03
• Last updated: 2021-01-26

Locations

4 sites across 1 country: Germany